SomnoMed (SOM) investor relations material

Executive summary

• Achieved record half-year revenue of $60.7 million (AUD 60.7 million), up 13% year-over-year, driven by strong demand in Europe and North America.

• EBITDA rose 35% to $7.8 million, with margin improvement from 11% to 13% due to operating leverage and delayed investments.

• Positive operating cash flow of $2.5 million after leases, though free cash flow was negative at $0.9 million due to planned capital expenditure.

• Manufacturing capacity increased by over 20%, improving turnaround times by more than 50% since June 2025.

• Strengthened leadership with appointments of a Chief Marketing Officer and Chief Transformation Officer.

Financial highlights

• Revenue grew 13% to $60.7 million compared to the prior year, with 8% growth in constant currency.

• EBITDA increased to $7.8 million from $5.8 million, with margin rising to 13%.

• Gross margin remained stable at 61.3% versus 61.6% a year ago.

• Net profit after tax was $792,000, reversing a prior year loss.

• Capital expenditure increased to $3.4 million from $1.4 million, mainly for manufacturing and R&D.

Outlook and guidance

• FY26 guidance reaffirmed: full-year revenue of $119–$126 million and EBITDA of $10–$12 million.

• Capital expenditure for FY26 expected to be $6–$8 million, focused on manufacturing expansion and R&D.

• Continued momentum anticipated in key markets, with disciplined cost control and targeted investment.

• FX assumptions for guidance reflect recent currency movements, especially USD and EUR.

• Ongoing manufacturing expansion and operational investments expected in 2H FY26.